Jan Gleichenhagen

Dr. Jan Gleichenhagen

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in European Journal of Cell Biology
Verified
Journal Article
Closed access
MAMeriyem Aktas
Meriyem Aktas
MWMirja Wessel
Mirja Wessel
SHStephanie Hacker
Stephanie Hacker
SKSonja Klüsener
Sonja Klüsener
JGJan Gleichenhagen
Jan Gleichenhagen
FNFranz Narberhaus
Franz Narberhaus

17 November 2014 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
LDLinna Danne
Linna Danne
MAMeriyem Aktas
Meriyem Aktas
JGJan Gleichenhagen
Jan Gleichenhagen
NGNadine Grund
Nadine Grund
DWDominic Wagner
Dominic Wagner
FNFranz Narberhaus
Franz Narberhaus

15 July 2011 in Journal of Bacteriology
Verified
Journal Article
Closed access
MAMeriyem Aktas
Meriyem Aktas
JGJan Gleichenhagen
Jan Gleichenhagen
RSRaphael Stoll
Raphael Stoll
FNFranz Narberhaus
Franz Narberhaus
The presence of the membrane lipid phosphatidylcholine (PC) in the bacterial membrane is critically important for many host-microbe interactions. The phospholipid N -methyltransferase PmtA from the plant pathogen Agrobacterium tumefaciens catalyzes the formation of PC by a three-step methylation of phosphatidylethanolamine via monomethylphosphatidylethanolamine and dimethylphosphatidylethanolamine. The methyl group is provided by S -adenosylmethionine (SAM), which is converted to S -adenosylhomocysteine (SAH) during transmethylation. Despite the biological importance of bacterial phospholipid N -methyltransferases, little is known about amino acids critical for binding to SAM or phospholipids and catalysis. Alanine substitutions in the predicted SAM-binding residues E58, G60, G62, and E84 in A. tumefaciens PmtA dramatically reduced SAM-binding and enzyme activity. Homology modeling of PmtA satisfactorily explained the mutational results. The enzyme is predicted to exhibit a consensus topology of the SAM-binding fold consistent with cofactor interaction as seen with most structurally characterized SAM-methyltransferases. Nuclear magnetic resonance (NMR) titration experiments and 14 C-SAM-binding studies revealed binding constants for SAM and SAH in the low micromolar range. Our study provides first insights into structural features and SAM binding of a bacterial phospholipid N -methyltransferase.

Verified
Journal Article
Open access
PDF file
JGJan Gleichenhagen
Jan Gleichenhagen
CAChristian Arndt
Christian Arndt
SCSwaantje Casjens
Swaantje Casjens
CMCarmen Meinig
Carmen Meinig
HGHolger Gerullis
Holger Gerullis
GJGeorg Johnen
Georg Johnen
Urine-based biomarkers for non-invasive diagnosis of bladder cancer are urgently needed. No single marker with sufficient sensitivity and specificity has been described so far. Thus, a combination of markers appears to be a promising approach. The aim of this case-control study was to evaluate the performance of an in-house developed enzyme-linked immunosorbent assay (ELISA) for survivin, the UBC® Rapid test, and the combination of both assays. A total of 290 patients were recruited. Due to prior bladder cancer, 46 patients were excluded. Urine samples were available from 111 patients with bladder cancer and 133 clinical controls without urologic diseases. Antibodies generated from recombinant survivin were utilized to develop a sandwich ELISA. The ELISA and the UBC® Rapid test were applied to all urine samples. Receiver operating characteristic (ROC) analysis was used to evaluate marker performance. The survivin ELISA exhibited a sensitivity of 35% with a specificity of 98%. The UBC® Rapid test showed a sensitivity of 56% and a specificity of 96%. Combination of both assays increased the sensitivity to 66% with a specificity of 95%. For high-grade tumors, the combination showed a sensitivity of 82% and a specificity of 95%. The new survivin ELISA and the UBC® Rapid test are both able to detect bladder cancer, especially high-grade tumors. However, the performance of each individual marker is moderate and efforts to improve the survivin assay should be pursued. A combination of both assays confirmed the benefit of using marker panels. The results need further testing in a prospective study and with a high-risk population.

1 December 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
NBNatalya Benderska-Söder
Natalya Benderska-Söder
JHJan Hovanec
Jan Hovanec
BPBeate Pesch
Beate Pesch
PGPeter J. Goebell
Peter J. Goebell
FRFlorian Roghmann
Florian Roghmann
BSBernd J. Schmitz-Dräger
Bernd J. Schmitz-Dräger

13 May 2020 in Biomarker Research
Verified
Journal Article
Open access
PDF file
TGthe MoMar study group
the MoMar study group
DWDaniel G. Weber
Daniel G. Weber
SCSwaantje Casjens
Swaantje Casjens
ABAlexander Brik
Alexander Brik
IRIrina Raiko
Irina Raiko
GJGeorg Johnen
Georg Johnen
Background: For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers. Methods: Candidate lncRNAs were identified in silico using previously published RNA expression profiles and verified using quantitative PCR (qPCR) in mesothelioma cell lines as well as human plasma samples from mesothelioma patients and asbestos-exposed controls. Results: GAS5 (growth arrest-specific transcript 5) as a single marker is marked by a low sensitivity of 14%, but the combination of GAS5 with calretinin and mesothelin increased the panel’s sensitivity from 64 to 73% at a predefined specificity of 97%. Circulating GAS5 is not affected by pleurectomy before blood collection, age, or smoking status. Conclusions: GAS5 is verified as an appropriate circulating marker for the supplement of calretinin and mesothelin to detect malignant mesothelioma. Although the sensitivity of GAS5 is too low for the use as a single marker, the addition of GAS5 as a third marker improves the performance of the established marker panel. The benefit of GAS5 for the detection of malignant mesothelioma at early stages needs to be validated in a prospective study.